Recursion Pharmaceuticals Inc (NASDAQ:RXRX) price on Thursday, January 16, fall -0.31% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.40.
A look at the stock’s price movement, the close in the last trading session was $6.42, moving within a range at $6.33 and $6.58. The beta value (5-Year monthly) was 0.802. Turning to its 52-week performance, $15.74 and $5.60 were the 52-week high and 52-week low respectively. Overall, RXRX moved -7.91% over the past month.
Recursion Pharmaceuticals Inc’s market cap currently stands at around $2.50 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 18.17M for the company’s revenue for the quarter, with a low and high estimate of 8M and 34M respectively. The average forecast suggests up to a 66.85% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 67.14M, representing a 50.61% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RXRX is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend RXRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RXRX’s current price about -7.74% and -7.32% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.64, while 7-day volatility ratio is 6.90% and 9.34% in the 30-day chart. Further, Recursion Pharmaceuticals Inc (RXRX) has a beta value of 0.85, and an average true range (ATR) of 0.64. Analysts have given the company’s stock an average 52-week price target of $11, forecast between a low of $6 and high of $12. Looking at the price targets, the low is 6.25% off current price level while to achieve the yearly target high, price needs to move -87.5%. Nonetheless, investors will most likely welcome a -71.87% jump to $11 which is the analysts’ median price.
If we refocus on Recursion Pharmaceuticals Inc (NASDAQ:RXRX), historical trading data shows that trading volumes averaged 15.78 over the past 10 days and 11.93 million over the past 3 months. The company’s latest data on shares outstanding shows there are 390.76 million shares.
The 17.13% of Recursion Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 57.91% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 73.74 million on 2024-12-31, giving us a short ratio of 4.38. The data shows that as of 2024-12-31 short interest in Recursion Pharmaceuticals Inc (RXRX) stood at 2058.0 of shares outstanding, with shares short rising to 67.85 million registered in 2024-11-29. Current price change has pushed the stock -5.33% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RXRX stock continues to rise going into the next quarter.
